• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Tevogen Bio Inc

< Previous 1 2 3 4 Next >
Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress
October 29, 2025
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest
October 15, 2025
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion
September 25, 2025
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID
September 23, 2025
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans
September 19, 2025
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston
September 10, 2025
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection
September 09, 2025
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform
September 08, 2025
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas
September 04, 2025
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2
September 03, 2025
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure
August 27, 2025
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health Equity
August 26, 2025
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions
August 25, 2025
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma
August 22, 2025
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
August 19, 2025
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum
August 19, 2025
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
Tevogen CEO Donates Personal Shares to Support Local Law Enforcement
August 18, 2025
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery
August 18, 2025
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected
August 14, 2025
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
August 13, 2025
From Tevogen Bio Inc
Via GlobeNewswire
Tickers MSFT TVGN TVGNW
Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion
August 11, 2025
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion
August 11, 2025
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow
August 11, 2025
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
August 11, 2025
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions
August 08, 2025
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy
August 07, 2025
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions
August 06, 2025
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
August 05, 2025
From Tevogen Bio Inc
Via GlobeNewswire
Tickers MSFT TVGN TVGNW
Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
August 01, 2025
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion
August 01, 2025
From Tevogen Bio Inc
Via GlobeNewswire
Tickers TVGN TVGNW
< Previous 1 2 3 4 Next >
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap